A phase II, randomized, double-blind, parallel-group, placebo-controlled, multicenter study to evaluate the safety and efficacy of rituximab (Mabthera/Rituxan) in adults with relapsing remitting multiple sclerosis

Trial Profile

A phase II, randomized, double-blind, parallel-group, placebo-controlled, multicenter study to evaluate the safety and efficacy of rituximab (Mabthera/Rituxan) in adults with relapsing remitting multiple sclerosis

Completed
Phase of Trial: Phase II

Latest Information Update: 24 Nov 2014

At a glance

  • Drugs Rituximab (Primary)
  • Indications Multiple sclerosis
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms HERMES
  • Sponsors Genentech
  • Most Recent Events

    • 14 Feb 2008 Results have been published in the New England Journal of Medicine.
    • 15 Oct 2007 Status changed from in progress to completed.
    • 13 Oct 2007 Results have been reported at ECTRMS 2007
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top